MiMedx Group/MDXG

$6.35

-1.39%
-
1D1W1MYTD1YMAX

About MiMedx Group

MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.

Ticker

MDXG

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Joseph Capper

Employees

895

Headquarters

Marietta, United States
Website
mimedx.com

MiMedx Group Metrics

BasicAdvanced
$946.41M
Market cap
29.37
P/E ratio
$0.22
EPS
1.40
Beta
-
Dividend rate
$946.41M
1.40406
$9.27
$3.26
768.92K
3.57
3.113
33.702
34.403
14.744
7.11%
32.86%
89.47%
42.03%
29.374
2.944
6.598
8.019
38.441
20.03%
209.19%
9%

What the Analysts think about MiMedx Group

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 6 analysts.
96.85% upside
High $14.00
Low $11.00
$6.35
Current price
$12.50
Average price target

MiMedx Group Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
61.52% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$86.8M
6.24%
Net income
$53.4M
528.24%
Profit margin
61.52%
491.54%

MiMedx Group Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 357.14%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.06
-
$0.06
$0.32
-
Expected
-$0.09
-$0.02
$0.05
$0.07
$0.05
Surprise
-30.77%
-
33.33%
357.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for MiMedx Group stock?

MiMedx Group (MDXG) has a market cap of $946.41M as of April 16, 2024.

What is the P/E ratio for MiMedx Group stock?

The price to earnings (P/E) ratio for MiMedx Group (MDXG) stock is 29.37 as of April 16, 2024.

Does MiMedx Group stock pay dividends?

No, MiMedx Group (MDXG) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next MiMedx Group dividend payment date?

MiMedx Group (MDXG) stock does not pay dividends to its shareholders.

What is the beta indicator for MiMedx Group?

MiMedx Group (MDXG) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the MiMedx Group stock price target?

The target price for MiMedx Group (MDXG) stock is $12.5, which is 96.85% above the current price of $6.35. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell MiMedx Group stock

Buy or sell MiMedx Group stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing